bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com

Investment analysts at StockNews.com began coverage on shares of bluebird bio (NASDAQ:BLUE) in a research report issued to clients and investors on Friday. The firm set a “sell” rating on the biotechnology company’s stock.

A number of other research firms have also commented on BLUE. JPMorgan Chase & Co. raised bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th. Wells Fargo & Company decreased their target price on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a research report on Monday, February 24th. Barclays upped their target price on shares of bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, December 31st. Finally, Baird R W cut shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $51.00.

bluebird bio Trading Up 1.1 %

Shares of NASDAQ BLUE opened at $3.79 on Friday. The firm’s 50 day moving average price is $5.61 and its 200-day moving average price is $7.82. bluebird bio has a 52-week low of $3.56 and a 52-week high of $28.60. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51. The company has a market cap of $36.85 million, a PE ratio of -0.10 and a beta of 0.76.

Institutional Investors Weigh In On bluebird bio

Large investors have recently made changes to their positions in the company. FMR LLC boosted its holdings in shares of bluebird bio by 8.1% in the third quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock worth $1,289,000 after buying an additional 186,903 shares during the last quarter. BNP Paribas Financial Markets raised its position in bluebird bio by 2,270.2% in the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 355,562 shares during the period. Captrust Financial Advisors boosted its stake in shares of bluebird bio by 48.2% during the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 77,293 shares during the last quarter. Verition Fund Management LLC bought a new stake in shares of bluebird bio during the 3rd quarter valued at $42,000. Finally, State Street Corp increased its stake in shares of bluebird bio by 1.1% in the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock worth $1,996,000 after purchasing an additional 43,382 shares in the last quarter. 87.43% of the stock is currently owned by institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.